敏感性耐药性检测显示，在单剂量奈韦拉平（NVP）给药后，部分妇女和婴儿体内携带K103N奈韦拉平（NVP）耐药突变的HIV-1变异株长期持续存在：HIVNET 012研究。

Sensitive drug-resistance assays reveal long-term persistence of HIV-1 variants with the K103N nevirapine (NVP) resistance mutation in some women and infants after the administration of single-dose NVP: HIVNET 012.

作者信息

Flys Tamara, Nissley Dwight V, Claassen Cassidy W, Jones Dana, Shi Chanjuan, Guay Laura A, Musoke Philippa, Mmiro Francis, Strathern Jeffrey N, Jackson J Brooks, Eshleman James R, Eshleman Susan H

机构信息

Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, Maryland 21205, USA.

出版信息

J Infect Dis. 2005 Jul 1;192(1):24-9. doi: 10.1086/430742. Epub 2005 Jun 1.

DOI:10.1086/430742

PMID:15942890

Abstract

BACKGROUND

The HIV Network for Prevention Trials (HIVNET) 012 trial showed that NVP resistance (NVPR) emerged in some women and children after the administration of single-dose nevirapine (SD-NVP). We tested whether K103N-containing human immunodeficiency virus (HIV)-1 variants persisted in women and infants 1 year or more after the administration of SD-NVP.

METHODS

We analyzed samples from 9 women and 5 infants in HIVNET 012 who had NVPR 6-8 weeks after the administration of SD-NVP. Samples were analyzed with the ViroSeq system and with 2 sensitive resistance assays, LigAmp and TyHRT.

RESULTS

ViroSeq detected the K103N mutation in 8 of 9 women and in 2 of 5 infants. LigAmp detected the K103N mutation at low levels in 8 of 9 women and in 4 of 5 infants. K103N was not detected by ViroSeq 12-24 months after the administration of SD-NVP but was detected by LigAmp in 3 of 9 women and in 1 of 5 infants. K103N was also detected in those samples by use of the TyHRT assay.

CONCLUSIONS

K103N-containing variants persist in some women and infants for 1 year or more after the administration of SD-NVP. Sensitive resistance assays may provide new insight into the impact of antiretroviral drug exposure on HIV-1 evolution.

摘要

背景

艾滋病预防试验网络（HIVNET）012试验表明，单剂量奈韦拉平（SD-NVP）给药后，部分妇女和儿童出现了奈韦拉平耐药（NVPR）。我们测试了含K103N的人类免疫缺陷病毒（HIV）-1变体在SD-NVP给药后1年或更长时间内是否在妇女和婴儿体内持续存在。

方法

我们分析了HIVNET 012中9名妇女和5名婴儿的样本，这些妇女和婴儿在SD-NVP给药后6-8周出现了NVPR。使用ViroSeq系统和两种敏感的耐药性检测方法LigAmp和TyHRT对样本进行分析。

结果

ViroSeq在9名妇女中的8名和5名婴儿中的2名中检测到K103N突变。LigAmp在9名妇女中的8名和5名婴儿中的4名中检测到低水平的K103N突变。SD-NVP给药后12-24个月，ViroSeq未检测到K103N，但LigAmp在9名妇女中的3名和5名婴儿中的1名中检测到了K103N。使用TyHRT检测方法在这些样本中也检测到了K103N。